Continue Reading
Full article on Yahoo Finance
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
Market Intelligence Analysis
AI-Powered 60% FREE-ANALYSIS-RULE-BASED-ANALYSIS
Why This Matters
Analysis of stock market developments showing bullish sentiment.
Sentiment
Bullish
AI Confidence
60%
Time Horizon
Short Term
Affected Symbols
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS ; NCT 06743776) evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis
AI Breakdown
Summary
Analysis of stock market developments showing bullish sentiment.
Time Horizon
Short Term
Original article published by
Yahoo Finance
on July 15, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.